Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cardiac assessment before doxorubicin treatment

Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85

Publish date:: October 19, 2018

Key clinical point: Performing left ventricular ejection fraction (LVEF) measurement before doxorubicin chemotherapy may not be helpful.

Major finding: Among diffuse large B-cell lymphoma (DLBCL) patients who had LVEF measured, the incidence of heart failure post treatment did not differ between patients who received doxorubicin and those who did not (P = 1.0).

Study details: A retrospective analysis of 291 patients diagnosed with DLBCL between 2001 and 2013.

Disclosures: The researchers reported having no competing interests.

Read the article here.

Citation:

Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85.

This Week's Must Reads

Phase II Trial of DNA Vaccine Encoding PAP in Patients with PCa ,

Utilization of Surgery for Post-prostatectomy Incontinence,

Claims Analysis of Advanced PCa Treatment Costs and Resource Use,

Testosterone Therapy Doesn't Increase Prostate Cancer Risk,

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced PCa,

Must Reads in Lymphoma & Plasma Cell Disorders

Cardiac assessment before doxorubicin treatment , Enns DL et al. Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-85

Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10

Outcomes Post-AlloSCT in DHL/DEL Lymphomas, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Herrera, et al

Anthracycline-Related CV Dysfunction Evaluated, Cancer; ePub 2017 Nov 7; Armenian, Mertens, et al

Adcetris Approved for Primary Cutaneous ALCL, FDA news release; 2017 Nov 9